Viridian Therapeutics, Inc./DE Proceeds from Related Party Debt
Viridian Therapeutics, Inc./DE (VRDN) reported Proceeds from Related Party Debt of $795.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2016-03-21.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRelatedPartyDebt · last filed 2016-03-21
- Viridian Therapeutics, Inc./DE proceeds from related party debt for the quarter ending 2014-12-31 was $0.00, a 100.00% decline year-over-year.
- Viridian Therapeutics, Inc./DE proceeds from related party debt for the quarter ending 2014-09-30 was $0.00, a 100.00% decline year-over-year.
- Viridian Therapeutics, Inc./DE proceeds from related party debt for the quarter ending 2014-06-30 was $695.00K.
- Viridian Therapeutics, Inc./DE proceeds from related party debt for the quarter ending 2014-03-31 was $100.00K.
- Viridian Therapeutics, Inc./DE proceeds from related party debt for fiscal 2014 was $795.00K, a 93.67% decline from fiscal 2013.
- Viridian Therapeutics, Inc./DE proceeds from related party debt for fiscal 2013 was $12.57M.
| Period end | Proceeds from Related Party Debt 3 month | Proceeds from Related Party Debt 6 month | Proceeds from Related Party Debt 9 month | Proceeds from Related Party Debt 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-21 | $0.00 derived: sum of 2 quarters · filed 2016-03-21 | $695.00K derived: sum of 3 quarters · filed 2016-03-21 | $795.00K 10-K · filed 2016-03-21 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $695.00K derived: sum of 2 quarters · filed 2015-11-13 | $795.00K 10-Q · filed 2015-11-13 | $1.54M derived: sum of 4 quarters · filed 2015-11-13 |
| 2014-06-30 | $695.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $795.00K 10-Q · filed 2015-08-14 | $1.54M derived: sum of 3 quarters · filed 2015-08-14 | $2.15M derived: sum of 4 quarters · filed 2015-08-14 |
| 2014-03-31 | $100.00K 10-Q · filed 2015-05-15 | $849.82K derived: sum of 2 quarters · filed 2015-05-15 | $1.45M derived: sum of 3 quarters · filed 2015-05-15 | |
| 2013-12-31 | $749.82K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $1.35M derived: sum of 2 quarters · filed 2015-03-27 | $12.57M 10-K · filed 2015-03-27 | |
| 2013-09-30 | $601.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | $11.82M 10-Q · filed 2014-11-14 | ||
| 2013-06-30 | $11.21M 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |